Articles mentioning Bristol-Myers Squibb (BMY)

Results 11 - 20 of 834 : Previous 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for BMY

Investing | April 18, 2016

5 Stocks to Supplement Your Social Security Benefits

ExxonMobil, AT&T, Deere & Co, Bristol-Myers Squibb, and Microsoft all offer compelling dividend yields that could boost income in retirement.

Investing | April 16, 2016

The Big Downside to Better Medicine? Higher Prices

Runaway drug spending is costing Americans billions of dollars every year.

Investing | April 15, 2016

Why Regulus Therapeutics Is Slumping 14% Today

Updated results for its clinical-stage hepatitis C drug failed to spark a rally.

Investing | April 13, 2016

What Caused Arrowhead Pharmaceuticals to Skyrocket 13% Today

New data from its trial of ARC-520 in hepatitis B ignited a rally.

Investing | April 13, 2016

3 Biotech Takeover Targets That Could Get Bought Soon

Kite Pharma, Medivation, Inc., and Portola Pharmaceuticals could all have suitors knocking on their door.

Investing | April 12, 2016

3 Nominations for Big Pharma's Riskiest Pipeline -- and Why They Qualify

Understanding the level of risk in a therapeutic pipeline leads to smarter investing. Our contributors tip you off on where to be wary, and what benchmarks to look for.

Investing | April 07, 2016

3 Drug Developers Pfizer Could Go After Now That the Allergan Deal Is Officially Dead

With Allergan now in the rearview mirror, Pfizer may seek to the move the needle by acquiring one of these three drug developers.

Investing | April 07, 2016

Ignore Exelixis, Inc.: Here Are 3 Better Stocks

Whether you want to stay with oncology or try your hand at antivirals or very small medical devices, any one of these three stocks is better than Exelixis.

Investing | March 31, 2016

3 Reasons Investors Can Buy Bristol-Myers Squibb

Fast-growing immuno-oncology and anticoagulant drugs and top-tier financials make this one company investors ought to consider buying.

Investing | March 15, 2016

Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb

After Exelexis' recent market beat-down, is it a better buy than the big pharma that fell off a patent cliff?

Results 11 - 20 of 834 : Previous 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for BMY